On December 5, 2024, Qiming Medical held its second extraordinary general meeting of shareholders, H shares shareholder meeting, and non-listed foreign shares shareholder meeting in Hangzhou. All proposed resolutions were passed, including the election of Mr. Gu Junhua as an independent non-executive director and several amendments to the company's articles of association. The procedures for these meetings complied with the relevant laws and regulations of China as well as the company's articles of association, and the voting results were legal and valid.At the extraordinary general meeting, both ordinary resolutions and special resolutions received support exceeding the required votes. The special resolutions included amendments to Article 2.07A and other amendments to the company's articles of association, all receiving...Show More

On December 5, 2024, Qiming Medical held its second extraordinary general meeting of shareholders, H shares shareholder meeting, and non-listed foreign shares shareholder meeting in Hangzhou. All proposed resolutions were passed, including the election of Mr. Gu Junhua as an independent non-executive director and several amendments to the company's articles of association. The procedures for these meetings complied with the relevant laws and regulations of China as well as the company's articles of association, and the voting results were legal and valid.At the extraordinary general meeting, both ordinary resolutions and special resolutions received support exceeding the required votes. The special resolutions included amendments to Article 2.07A and other amendments to the company's articles of association, all receiving over two-thirds approval. The resolutions of the H shares shareholder meeting and non-listed foreign shares shareholder meeting were also passed, demonstrating the shareholders' support for the company's governance.In addition, due to the appointment of Mr. Gu Junhua, the board of directors now fully meets the requirements of the Hong Kong listing rules, including the minimum number and proportion of independent non-executive directors. These changes will contribute to the company's future compliance operations and the optimization of its governance structure.